Search PubMed⌕ Search

Biomedical subjects

M Brausi

Publications and source records attributed to M Brausi.

32 records · Page 2Linked to original sources
PubMed1991

Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer.

M-VEC (methotrexate, vinblastine, epidoxorubicin and cisplatin), a new combined drug regimen in which epidoxorubicin has been substituted to adriamycin to reduce the toxicity of the original M-VAC chemotherapy, has been tested in 23 patients with locally advanced transitional cell bladder cancer (TCBC) (stage T2-T4 No Mo). After two to four courses, an objective response was observed in 19 patients, with 13 clinical complete responses. Seven patients underwent cystectomy after chemotherapy: one patient had no residual tumor on bladder specimens, five patients had a surgical eradication of the disease, while one patient had only a partial resection. Eight relapses of bladder carcinoma were observed, three among the surgically treated patients and five among patients who did not undergo cystectomy, with a median time-to-relapse of 9.7 months. Progression-free survival at 24 months was 52.3%. M-VEC regimen appears to be effective in locally advanced TCBC, with acceptable toxicity.

Adult↗
PubMed1991

Recombinant alpha interferon in metastatic renal cell carcinoma. A cooperative phase II study.

A total of 61 evaluable patients with advanced renal cell carcinoma have been treated with 3 x 10(6) IU per square meter of body surface with recombinant alpha 2b interferon three times a week within a Cooperative Phase II Study. Toxic death for terminal renal failure occurred in 1 patient (1.63%), and toxicities greater than WHO grade 2 were present in 10 cases (16%). The overall response rate after six months of treatment was 13.1% (partial response 4, minor response 4). Two complete responses were obtained at nine and fifteen months (3.3%). Long-lasting stabilization of disease was 13.1 percent.

Adult↗
PubMed1991

Morbidity of modified pelvic lymphadenectomy and radiotherapy for prostatic cancer.

The records of 63 patients treated by pelvic lymphadenectomy and radiotherapy at the University of Tennessee, Memphis, Baptist Memorial Hospital of Memphis, and the Memphis Veterans Affairs Hospital were reviewed. Of those patients, 45 received external beam radiation therapy to the prostate while 16 were treated by Iodine-125 implantation. Two patients had only staging lymphadenectomy. The incidence of postoperative and late complications were analyzed.

Aged↗
PubMed1990

Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer.

Methotrexate (MTX) has activity in transitional cell carcinoma (TCC) in man and some have suggested an advantage of high-dose methotrexate versus the standard dose in controlling tumor growth and prolonging survival. MBT-2, a poorly differentiated TCC induced by the carcinogen FANFT, is both grossly and histologically similar to human TCC and has been used as an animal model. One hundred twenty C3H/HE female mice were injected in the hind limb with 7.5 X 10(4) MBT-2 tumor cells. When palpable tumors developed in all animals, therapy was initiated. Animals were randomized into a control group and nine treatment groups as follows: cisplatin (DDP), MTX32 mg, MTX50 mg, MTX80 mg, DDP + MTX32, MTX50 + Leucovorin, MTX80 + Leucovorin, DDP + MTX50 + Leucovorin, DDP + MTX80 + Leucovorin. The combination of MTX50 mg with Leucovorin + DDP and DDP alone were the two most effective regimens in controlling tumor growth and prolonging survival. No statistically significant difference was observed between the group treated by high-dose MTX alone and those treated by low-dose MTX. No toxicity was observed even when high doses of MTX were used.

Animals↗
PubMed1990

Clonal growth requirements of human bladder tumor cell lines.

We have serially investigated the role of nutrients and growth factors for their ability to support the clonal growth of human bladder tumor cell lines. Five established human bladder tumor cell lines were selected for study of their requirements for clonogenic growth in semisolid cultures. We identified an "optimal medium" to be Alpha MEM medium, 15% horse serum, five micrograms/ml. of transferrin, five micrograms/ml. of insulin and 30 ng./ml. of epidermal growth factor. The "optimal assay" enhanced the growth of human bladder tumor cell lines 2.5 times compared to the standard clonogenic assay. The resulting medium is less complicated to maintain, less expensive and supports the growth of human bladder tumor cell lines better than the standard clonogenic assay.

Cell Line↗
PubMed1989

Progression and complications after external beam radiation therapy for carcinoma of prostate.

Sixty patients with prostatic carcinoma localized to the pelvis have been treated by external beam radiation therapy: 2 patients (2%) were Stage A, 12 (20%) Stage B, 14 (23%) Stage C, and 32 (53%) Stage D1. Twenty-two patients received adjuvant therapy (11 estramustine phosphate [Estracyt] and 11 cyclophosphamide [Cytoxan]) after radiation. Progression occurred in 22 patients (37%): 6 (10%) had local recurrence while 16 (27%) failed distally. The incidence of late major complications was 12 percent.

Adenocarcinoma↗
PubMed1987

Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer.

Using the FANFT-induced tumors MBT-2 and MBT-683 we compared the response rate and survival using cisplatin alone and in various combinations with doxorubicin hydrochloride (Adriamycin), mitomycin C, methotrexate, and vinblastine. Sixty C3H/He female mice received 7.5 x 10(4) MBT-2 cells in the right hind limb. The animals were randomly divided into a control group and four treatment groups as follows: cisplatin, 6.0 mg/kg; cisplatin, 2.0 mg/kg, vinblastine, and methotrexate; cisplatin, 2.0 mg/kg, vinblastine, methotrexate, and doxorubicin hydrochloride; and cisplatin, 2.0 mg/kg, vinblastine, methotrexate, and mitomycin C. The drugs were given intraperitoneally on days 7, 14, and 21. The study was repeated using MBT-683. Drug effect on tumor diameter and survival were compared. Cisplatin alone was as effective in MBT-2 and more effective in MBT-683 in reducing tumor volume and increasing survival than the various combinations. The higher tolerable dose of cisplatin used as a single agent probably accounts for these results and suggests that cisplatin is the most effective agent in these combination therapy regimens.

Animals↗
PubMed1986

Local seeding of anaplastic carcinoma of prostate after needle biopsy.

We present the seventh case of perineal localization of anaplastic carcinoma after needle biopsy of the prostate. The patient first had cryosurgery and bilateral orchiectomy followed by hormonal therapy (estrogens) and chemotherapy. The surgical excision of the mass was performed, but he died a few days later of metastatic disease.

Biopsy, Needle↗
PubMedDate not supplied

Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results.

The purpose of this study was to clarify the actual therapeutic potential of a new transdermal drug delivery system (electromotive drug administration; EMDA) for selected patients with Peyronie's disease. Forty patients with Peyronie's disease were treated by electromotive administration of the 3-drug association orgotein-dexamethasone-lidocaine in a double-blind, placebo-controlled, partial crossover study (study 1). Another 25 patients were treated by EMDA with a combination of verapamil-dexamethasone in an uncontrolled study (study 2). Treatment sessions lasted 20 minutes each and took place 3 times a week for 3 weeks with a current of 3 mA. Patients were assessed before treatment and at 1- and 3-month follow-up examinations. Assessments were based on sexual history, physical examination, and dynamic color Doppler ultrasonographic results. Adverse effects of EMDA were not reported. In study 1, the clinical results observed after treatment proved to be significantly better than those of the placebo. Penile pain disappeared in all patients in both studies. Penile lesion (nodule or plaque) either disappeared or significantly improved in 79% and 90% of patients treated by the 3- and 2-drug association, respectively. The improvement of penile deformity also was notable although it did not match the effect observed on penile nodules or plaque (62% and 88%, in studies 1 and 2, respectively). In both studies, more than 80% of patients reported a definite amelioration of penile rigidity, which paralleled the improvement of penile dynamic color Doppler ultrasonographic parameters. Overall, the combination of verapamil-dexamethasone achieved better clinical results than the 3-drug combination. Electromotive drug administration is a novel technique capable of safely achieving satisfactory results in selected patients with Peyronie's disease not only in terms of improvement of patient's symptoms but also due to the reduced need for penile surgery.

Administration, Cutaneous↗
PubMedDate not supplied

[Primary transitional-cell carcinoma of the male anterior urethra].

Primary carcinomas of the male anterior urethra account for less than 1% of all urological carcinoma. The majority of these neoplasias develop of the posterior part of the urethra (proximal portion). The most common histotype is the squamous-cellular carcinoma. We have only found 4 other published reports of primary transitional carcinoma of the male anterior urethra. The paper discusses the diagnostic and therapeutic procedures employed in these rare cases.

Aged↗